Six in 10 Survivors of Moderate-to-Severe TBI Report Chronic Pain
10 Jan 2024
Clinical Result
WEDNESDAY, Jan. 10, 2024 -- Chronic pain impacts approximately 60 percent of survivors of moderate-to-severe traumatic brain injury (TBI), according to a study published in the January/February issue of The Journal of Head Trauma Rehabilitation.
Cynthia Harrison-Felix, Ph.D., from Craig Hospital in Englewood, Colorado, and colleagues estimated the prevalence of chronic pain after TBI and identified factors associated with chronic pain. The analysis included 3,804 participants who had been hospitalized with moderate-to-severe TBI.
The researchers found that 46 percent of participants reported current chronic pain, while 14 percent reported past (postinjury) chronic pain. There was little clinical difference in sociodemographic and injury characteristics between those reporting current, past, or no chronic pain. However, individuals with current chronic pain had worse functional outcomes versus individuals in the past pain or no pain groups. Current chronic pain was also associated with higher treatment utilization rates versus past pain.
"The implications of chronic pain for functional outcomes support inclusion of pain metrics in prognostic models and observational studies in this population," the authors write. "Future research is needed to proactively identify those at risk for the development of chronic pain and determine the efficacy and access to pain treatment."
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.